Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Subjects With Idiopathic Overactive Bladder (iOAB) and Urinary Incontinence

The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.

Study Overview

• Status: Completed
• Conditions: Idiopathic Overactive Bladder With Urinary Incontinence
• Intervention / Treatment: Drug: Trospium-Releasing Intravesical System (TAR-302-5018)

• Study Type: Interventional
• Enrollment (Actual): 43
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Tucson, Arizona, United States, 85715
      • Urological Associates of Southern Arizona
  • California
    • San Diego, California, United States, 92108
      • Medical Center for Clinical Research
  • Florida
    • Pompano Beach, Florida, United States, 33060
      • Clinical Research Center of Florida
  • Louisiana
    • New Orleans, Louisiana, United States, 70115
      • DelRicht Clinical Research, LLC
  • Massachusetts
    • Watertown, Massachusetts, United States, 02472
      • Bay State Clinical Trials, Inc
  • Michigan
    • Royal Oak, Michigan, United States, 48073
      • William Beaumont Hospital - Royal Oak
    • Troy, Michigan, United States, 48084
      • Michigan Institute of Urology
  • New Jersey
    • Voorhees, New Jersey, United States, 08043
      • New Jersey Urology
  • New York
    • Garden City, New York, United States, 11530-1664
      • AccuMed Research
    • New York, New York, United States, 10016
      • Manhattan Medical Resear
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27103
      • UWCR - Lyndhurst Gynecologic Associates
  • Virginia
    • Virginia Beach, Virginia, United States, 23462
      • Urology of Virginia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria (Part 1):

1. Symptoms of overactive bladder (OAB) (frequency/urgency) with urge urinary incontinence or mixed urinary incontinence with a predominant urge component for at least 6 months

   • 8 or more voids per 24 hours as recorded in a diary

   • At least 4 incontinence episodes associated with urgency recorded in a 3-day diary.

     • At least 1 episode must occur per each 24 hour day
2. Inadequate response or limiting side effects with anticholinergics for the treatment of OAB

Exclusion Criteria (Part 1):

1. Age <18 years.
2. OAB caused by neurological condition.
3. Presence of significant renal dysfunction at screening (Glomerular Filtration Rate <30 mL/min).
4. Presence of significant polyuria of any cause at screening (urine output >4,000 mL/day).
5. History of pelvic radiation.
6. History of either bladder cancer or bladder pathology that the investigator deems unfit for study inclusion.
7. Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.
8. Subjects with any bladder or urethral anatomic feature that may prevent the safe placement, indwelling use, or removal of TAR 302 5018.
9. In the opinion of the investigator, the subject has a history of significant stress urinary incontinence.
10. Subjects with active bladder stones or history of bladder stones <6 months prior to study entry.
11. History of recurrent symptomatic urinary tract infections (UTIs) (>4 per 1 year).
12. Subjects with either urinary retention or gastric retention or uncontrolled narrow-angle glaucoma.
13. A post-void residual volume (PVR) of 300 mL or greater
14. Subjects with known hypersensitivity to trospium, chemically-related drugs, or component excipients.
15. Subjects with known hypersensitivity to the device materials, including silicone and nitinol.
16. Subjects actively taking oral trospium.
17. The addition of a new or a change in dose to a current medication for the treatment of OAB (i.e. anticholinergics, beta-3 adrenergic agonists, antispasmodics, antidepressants, or hormones) within 30 days prior to signing the informed consent form (ICF). A stable dose must continue through the final study visit. If previously used and discontinued, these medications must have been stopped for >2 weeks prior to Day 0.
18. Intravesical onabotulinum toxin use within the last 9 months prior to the Screening Visit.
19. Intravesical anticholinergic medications within the last 30 days prior to the Screening Visit.
20. History of non-medication based therapy (i.e. InterStim therapy) for the treatment of OAB. History of non-invasive neuromodulation (i.e. Percutaneous Tibial Nerve Stimulation (PTNS)) is allowed if discontinued at least 8 weeks prior to Study Day 0.
21. Female subject who is pregnant (as verified by urine test at time of screening) or lactating or of childbearing potential and not using acceptable methods of contraception.
22. Subject has a medical condition that may cause noncompliance with the study protocol.
23. Subject refuses to provide written informed consent.
24. Subject will be unable or unwilling to complete the questionnaires, diaries, or attend all protocol mandated study visits.
25. Participation in another drug, device, or behavioral study within 60 days prior to the Screening Visit.
26. History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.

27. History of any of the following within 3 months prior to Screening Visit:

    • Major illness/major surgery (requiring hospitalization), including pelvic, lower back surgery or procedure unrelated to bladder cancer; most outpatient procedures are not exclusionary
    • Renal or ureteral stone disease or instrumentation
    • Childbirth
28. Difficulty providing blood samples.
29. Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.

Inclusion Criteria (Part 2):

1. Symptoms of idiopathic overactive bladder (iOAB) (frequency/urgency) with urge urinary incontinence or mixed urinary incontinence with a predominant urge component for at least 6 months.

   • 8 or more voids per 24 hours as recorded in a diary

   • At least 4 incontinence episodes associated with urgency recorded in a 3-day diary.

     1. At least 1 episode must occur per each 24 hour day
2. In the opinion of the investigator, the subject has experienced an inadequate response to or limiting side effects with prior oral medications for the treatment of OAB.

Exclusion Criteria (Part 2):

1. Age <18 years.
2. Neurologic bladder condition.
3. Subjects with Diabetes Mellitus (both Type 1 & Type 2) must demonstrate optimal glycemic control with HbA1c levels < 7.5 % and an absence of significant glucosuria defined as 3+ glucose via dipstick at screening.
4. Presence of significant polyuria of any cause at screening (urine output >3,000 mL/day).
5. Presence of nocturnal polyuria at time of study screening defined as >30% of total 24-hour urine collected from time of evening (P.M.) sleep and inclusive of the first morning (A.M.) void.
6. History of pelvic irradiation.
7. History of either bladder cancer or bladder pathology that the investigator deems unfit for study inclusion.
8. Currently uses intermittent catheterization (IC) to empty the bladder within 30 days of Day 0.
9. Subjects with any bladder or urethral anatomic feature (e.g., urethral stricture) that in the opinion of the investigator may prevent the safe placement, indwelling use, or removal of IP.
10. Subjects with active bladder stones or history of bladder stones < 6 months prior to study entry.
11. Gross hematuria within 30 days of Day 0.
12. History of uncontrolled bleeding, bleeding diathesis, or underlying coagulopathy within 30 days of Day 0.
13. In the opinion of the investigator, the subject has a history of predominance of significant stress urinary incontinence.
14. History of > 2 symptomatic urinary tract infections in the 6-months prior to Day 0.
15. Subjects with either urinary retention or gastric retention or uncontrolled narrow-angle glaucoma within 90 days of Day 0.
16. A post-void residual volume (PVR) of 100-mL or greater.
17. Subjects with known hypersensitivity to trospium, chemically-related drugs, or component excipients.
18. Subjects with known hypersensitivity to the device materials, including silicone and nitinol.
19. Anticholinergic or beta-3 agonist use for the treatment of urge urinary incontinence < 2 weeks prior to Day 0.
20. History of intravesical onabotulinum toxin use within the last 9 months prior to the Screening Visit.
21. Intravesical anticholinergic medications within the last 14 days prior to the Screening Visit.
22. History of procedural-based neuromodulation therapy (e.g. InterStim therapy, Percutaneous Tibial Nerve Stimulation [PTNS]) for the treatment of OAB.
23. Female subject who is pregnant (as verified by serum test at time of screening) or lactating.
24. Subject has, in the opinion of the investigator, a medical condition that may cause noncompliance with the study protocol.
25. Subject who is unable or unwilling to complete the questionnaires, diaries, or attend all protocol mandated study visits.
26. Participation in another drug, device, or behavioral study within 60 days prior to the Screening Visit.
27. History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder, or other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.

28. History of any of the following within 3 months prior to Screening Visit:

    i. Major illness/major surgery (requiring hospitalization), including pelvic, lower back surgery or procedure; most outpatient procedures are not exclusionary.

    ii. Childbirth.

29. History of prostatic biopsy or surgery (ablative or non-ablative) within 6 months prior to Day 0.
30. History of significant pelvic organ prolapse (Grade >/= 3).
31. Difficulty providing blood samples.
32. Known history of drug or alcohol dependency within 12 months of screening.
33. Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TAR-302-5018 (42-day Indwelling); Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.	Drug: Trospium-Releasing Intravesical System (TAR-302-5018); TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Experimental: TAR-302-5018 (84-day Indwelling); Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.	Drug: Trospium-Releasing Intravesical System (TAR-302-5018); TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of TAR-302-5018 assessed throughout the study based on reported AEs (Part 1)	Safety will be assessed throughout the study based on reported AEs, investigational product events (IPEs), physical examinations (PEs), vital signs, clinical laboratory tests, scheduled cystoscopic examinations, bladder ultrasounds, bladder post-void residual volume (PVR), and the use of concomitant medications.	Upon insertion, 42-day continuous exposure, and removal
Safety of TAR-302-5018 assessed throughout the study based on reported AEs (Part 2)	Safety will be assessed throughout the study based on reported AEs, investigational product events (IPEs), physical examinations (PEs), vital signs, clinical laboratory tests, scheduled cystoscopic examinations, bladder ultrasounds, bladder post-void residual volume (PVR), and the use of concomitant medications.	Upon insertion, 84-day continuous exposure, and removal

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tolerability of TAR-302-5018 (Part 1)	Percent of subjects who are tolerant of TAR-302-5018 indwelling for the designated period of time and do not require TAR-302-5018 removal prior to the scheduled date of removal due to meeting any of the Subject Stopping Criteria or other drug or device constituent related adverse event.	Upon insertion, 42-day continuous exposure, and removal
Tolerability of TAR-302-5018 (Part 2)	Percent of subjects who are tolerant of TAR-302-5018 indwelling for the designated period of time and do not require TAR-302-5018 removal prior to the scheduled date of removal due to meeting any of the Subject Stopping Criteria or other drug or device constituent related adverse event.	Upon insertion, 84-day continuous exposure, and removal
Pharmacokinetic Analysis of Plasma and Urine (Part 1)	Analysis of plasma trospium exposure and urinary trospium exposure.	From Day 0 to Day 56
Pharmacokinetic Analysis of Plasma and Urine (Part 2)	Analysis of plasma trospium exposure and urinary trospium exposure.	From Day 0 to Day 112
Reduction in incontinence over baseline (Part 1)	A negative change from baseline in number of daily episodes of urinary incontinence, where incontinence is defined as an incident of involuntary loss of urine.	From Day 0 to Day 84
Reduction in incontinence over baseline (Part 2)	A negative change from baseline in number of daily episodes of urinary incontinence, where incontinence is defined as an incident of involuntary loss of urine.	From Day 0 to Day 112
Reduction in daily micturition episodes (Part 1)	A negative change from baseline in the number of times a subject urinates into the toilet.	From Day 0 to Day 56
Reduction in daily micturition episodes (Part 2)	A negative change from baseline in the number of times a subject urinates into the toilet.	From Day 0 to Day 112
Increase in voided volume per micturition (Part 1)	An increase over baseline as measured over separate 24-hour periods.	From Day 0 to Day 56
Increase in voided volume per micturition (Part 2)	An increase over baseline as measured over separate 24-hour periods.	From Day 0 to Day 112

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of Life (Part 1)	Evidence of improvement in QoL as assessed by the OAB-q Short Form.	From Day 0 to Day 84
Quality of Life (Part 2)	Evidence of improvement in QoL as assessed by the OAB-q Short Form.	From Day 0 to Day 112

Collaborators and Investigators

• Sponsor: Taris Biomedical LLC
• Investigators: Study Director: Christopher Cutie, MD, TARIS Biomedical, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2017
• Primary Completion (Actual): September 27, 2019
• Study Completion (Actual): September 27, 2019

Study Registration Dates

• First Submitted: April 6, 2017
• First Submitted That Met QC Criteria: April 11, 2017
• First Posted (Actual): April 12, 2017

Study Record Updates

• Last Update Posted (Actual): January 13, 2020
• Last Update Submitted That Met QC Criteria: January 10, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Urologic Diseases; Urinary Bladder Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Urination Disorders; Elimination Disorders; Urinary Bladder, Overactive; Urinary Incontinence; Enuresis; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Urological Agents; Trospium chloride
• Other Study ID Numbers: TAR-302-103

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No